Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The targeted oncologic is simultaneously approved in Europe for first-line treatment of patients with advanced non-small cell lung cancer.
You may also be interested in...
Handicappers Debate Chances Of Genentech’s Avastin In Breast Cancer
As clock ticks down to tomorrow’s user fee date for Avastin, “ambivalent and ambiguous” agency hard to outguess, analyst tells “The Pink Sheet” DAILY.
Handicappers Debate Chances Of Genentech’s Avastin In Breast Cancer
As clock ticks down to tomorrow’s user fee date for Avastin, “ambivalent and ambiguous” agency hard to outguess, analyst tells “The Pink Sheet” DAILY.
FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5
ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.